ES2299508T3 - Profarmacos para ligandos del receptor nmda. - Google Patents

Profarmacos para ligandos del receptor nmda. Download PDF

Info

Publication number
ES2299508T3
ES2299508T3 ES01965201T ES01965201T ES2299508T3 ES 2299508 T3 ES2299508 T3 ES 2299508T3 ES 01965201 T ES01965201 T ES 01965201T ES 01965201 T ES01965201 T ES 01965201T ES 2299508 T3 ES2299508 T3 ES 2299508T3
Authority
ES
Spain
Prior art keywords
compound
formula
acid
piperidin
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01965201T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fisher
Marie-Paule Heitz Neidhart
Joerg Huwyler
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2299508T3 publication Critical patent/ES2299508T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES01965201T 2000-08-21 2001-08-20 Profarmacos para ligandos del receptor nmda. Expired - Lifetime ES2299508T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
ES2299508T3 true ES2299508T3 (es) 2008-06-01

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01965201T Expired - Lifetime ES2299508T3 (es) 2000-08-21 2001-08-20 Profarmacos para ligandos del receptor nmda.

Country Status (35)

Country Link
US (1) US6407235B1 (https=)
EP (1) EP1313703B1 (https=)
JP (1) JP4162991B2 (https=)
KR (1) KR100589991B1 (https=)
CN (1) CN1227230C (https=)
AR (1) AR030373A1 (https=)
AT (1) ATE386022T1 (https=)
AU (2) AU8589401A (https=)
BR (1) BR0113348A (https=)
CA (1) CA2419279C (https=)
CY (1) CY1107937T1 (https=)
CZ (1) CZ303319B6 (https=)
DE (1) DE60132782T2 (https=)
DK (1) DK1313703T3 (https=)
EC (1) ECSP034489A (https=)
EG (1) EG24293A (https=)
ES (1) ES2299508T3 (https=)
HR (1) HRP20030125B1 (https=)
HU (1) HU229802B1 (https=)
IL (1) IL154254A0 (https=)
JO (1) JO2289B1 (https=)
MA (1) MA26947A1 (https=)
MX (1) MXPA03001311A (https=)
MY (1) MY136065A (https=)
NO (1) NO324941B1 (https=)
NZ (1) NZ523990A (https=)
PA (1) PA8525601A1 (https=)
PE (1) PE20020291A1 (https=)
PL (1) PL204215B1 (https=)
PT (1) PT1313703E (https=)
RS (1) RS51467B (https=)
RU (1) RU2272027C2 (https=)
SI (1) SI1313703T1 (https=)
WO (1) WO2002016321A1 (https=)
ZA (1) ZA200300894B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1265864A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CA2633010A1 (en) * 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
EP1973872A4 (en) 2006-12-19 2012-05-09 Methylgene Inc HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF
PL4001272T3 (pl) 2013-11-05 2025-02-10 Astrazeneca Ab Proleki antagonisty nmda

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
KR100589991B1 (ko) 2006-06-15
US6407235B1 (en) 2002-06-18
JO2289B1 (en) 2005-09-12
CY1107937T1 (el) 2013-09-04
RS51467B (sr) 2011-04-30
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28
HRP20030125A2 (en) 2005-02-28
JP4162991B2 (ja) 2008-10-08
PE20020291A1 (es) 2002-04-17
DE60132782T2 (de) 2009-02-05
SI1313703T1 (sl) 2008-06-30
CZ303319B6 (cs) 2012-08-01
MY136065A (en) 2008-08-29
PL204215B1 (pl) 2009-12-31
NO20030781D0 (no) 2003-02-19
EP1313703A1 (en) 2003-05-28
AR030373A1 (es) 2003-08-20
KR20030022417A (ko) 2003-03-15
PT1313703E (pt) 2008-03-25
AU2001285894B2 (en) 2006-06-15
EG24293A (en) 2009-01-08
BR0113348A (pt) 2003-07-08
DK1313703T3 (da) 2008-05-19
HRP20030125B1 (en) 2011-07-31
ATE386022T1 (de) 2008-03-15
MXPA03001311A (es) 2003-06-30
EP1313703B1 (en) 2008-02-13
HUP0301548A2 (hu) 2003-08-28
AU8589401A (en) 2002-03-04
IL154254A0 (en) 2003-09-17
DE60132782D1 (de) 2008-03-27
CN1227230C (zh) 2005-11-16
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
CA2419279C (en) 2008-10-14
MA26947A1 (fr) 2004-12-20
CZ2003492A3 (cs) 2004-01-14
NO20030781L (no) 2003-02-19
PA8525601A1 (es) 2002-04-25
JP2004506715A (ja) 2004-03-04
US20020040037A1 (en) 2002-04-04
WO2002016321A1 (en) 2002-02-28
ZA200300894B (en) 2004-04-30
ECSP034489A (es) 2003-03-31
RU2272027C2 (ru) 2006-03-20
CA2419279A1 (en) 2002-02-28
PL361387A1 (en) 2004-10-04
NZ523990A (en) 2004-09-24
CN1447793A (zh) 2003-10-08
HUP0301548A3 (en) 2010-03-29

Similar Documents

Publication Publication Date Title
ES2748599T3 (es) Compuestos terapéuticos de isoxazol
CN109641904B (zh) 用于治疗和预防病毒感染的7-取代的磺亚氨酰基嘌呤酮化合物
TW202124374A (zh) Ras蛋白降解劑、其醫藥組合物及其治療應用
CN116368139A (zh) 用于治疗疼痛的nav1.7的非水合酮类抑制剂
US8624052B2 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
JPH07505407A (ja) インドール誘導体
PT92010A (pt) Processo para a preparacao de derivados de furo-e de tieno-piridina
EP2066662B1 (en) Serine hydrolase inhibitors
WO2012065110A2 (en) S-protected cysteine analogs and related compounds
ES2299508T3 (es) Profarmacos para ligandos del receptor nmda.
PT1641787E (pt) Dicetopiperazinas substituídas e sua utilização como antagonistas da oxitocina
CA2714966A1 (en) Arylmethylidene heterocycles as novel analgesics
AU2001285894A1 (en) Prodrugs to NMDA receptor ligands
ES2230685T3 (es) Quinoxalinadionas.
ES2257343T3 (es) Sal de meglumina de un compuesto de acido quinolincarboxilico especifico activo sobre los receptores de nmda.
CN114957270B (zh) 一种s（+）-普拉洛芬衍生物及其制备方法与用途
CN117700417B (zh) 一种脱氧鸭嘴花酮碱衍生物及其制备方法和应用
JP2008201675A (ja) ムチリン誘導体
HK40007010A (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
JPH1087485A (ja) 神経細胞死抑制剤
HK40007517B (en) Immunomodulator compounds
HK40007517A (en) Immunomodulator compounds
BR112019003519B1 (pt) Compostos de sulfonimidoilpurinona 7-substituídos para o tratamento e profilaxia de infecção por vírus